Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 (Verdinexor) in Spontaneous Canine Cancer: Results of Phase I and Phase II Clinical Trials PDF (1.17 MB) Read MorePresentation The Combination of SELINEXOR (KPT-330), a Selective Inhibitor of Nuclear Export (SINE), and the FLT3 Inhibitor QUIZARTINIB Shows Anti-Tumor Activity in Acute Myeloid Leukemia (AML) In-Vitro and In-Vivo PDF (1.21 MB) Read MorePresentation Anti-Tumor Activity of SELINEXOR (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE), ± Dexamethasone in Multiple Myeloma Preclinical Models and Translation in Patients with Multiple Myeloma PDF (3.16 MB) Read MorePresentation A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) Selexinor (KPT-330) in Patients with Relapsed / Refractory Acute Myeloid Leukemia (AML) PDF (4.15 MB) Read MorePresentation A first in class, first in human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors PDF (833.79 KB) Read MorePresentation A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients with Relapsed / Refractory Acute Myeloid Leukemia (AML) PDF (744.21 KB) Read MorePresentation Pre-Clinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients with Platinum Resistant/Refractory Ovarian Cancer (OvCa) PDF (1.07 MB) Read MorePresentation A Phase 1b Food Effect Study of the First-in-Class, Oral, Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Sarcomas PDF (2.68 MB) Read MorePresentation A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (selinexor) in Patients with Heavily Pretreated Non-Hodgkin’s Lymphoma (NHL) PDF (1.70 MB) Read MorePaper Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. External Link Read More Previous 1 … 16 17 18 19 20 … 22 Next